Table 4 Psychometric properties of selected health utilities measures in HIV population

EQ-5D-3L*

HIV+ patient [18,26-46]

Developing [37-39,41,46]

16-2261

0.81-0.86 [39]

0.78 [18]

MOS-HIV [27]

SF36 (r = 0.55-0.74) [18]

CD4 count [18,28,38]

HIV stages [29,36]

Improve over time [30]

Decline after diagnosis of AE [26,27,35,40]

0.0 [18,26-28,37,47]

12.4 - 39.7 [18,26-28,32,37,47]

SF6D (r = 0.74) [18]

GBV-C status [31]

ART* status [33]

Decline after health status worse [18]

WHOQOL-BREF (r = 0.31-0.60) [37]

SAE status [34]

Decline after CD4 and VL decline [32]

AQOL (r = 0.539) [41]

Viral load [28]

CD4 count group [32,37]

Developed [18,26-36,40,42-45,47]

HUI3 (r = 0.551) [41]

Improve when CD4 improve [38]

VAS (r = 0.41-0.80) [18,28,29,39]

Viral load group [32]

Decline before and after diagnosis of SAE* [35,40]

MOS-HIV (r = 0.40-0.72) [26,28,29,32,47]

EQ-5D-5L*

HIV+ patients [48]

Developing [48]

1016

0.85 [48]

-

-

VAS (r = 0.73) [48]

HIV stages [48]

-

-

CD4 count group [48]

Global rating of HRQoL (r = 0.36) [48]

Duration of ART [48]

15D

HIV+ patients [18]

Developed [18]

60

-

0.9 [18]

-

SF36 (r = 0.59-0.80) [18]

CD4 count [18]

Change follow the change of health status [18]

0 [18]

10-12 [18]

VAS (r = 0.73) [18]

Viral load [18]

HUI2*

HIV+ patients [34]

Developed [34]

57

-

-

-

-

-

-

-

HUI3*

HIV+ patient [26,35,40,41,49]

Developing [41]

57-1200

-

-

-

MOS-HIV (r = 0.34-0.70) [26,47]

CD4 count [35,40,49]

Decline after diagnosis of AE* [26]

0-3.2 [26,47]

3.15-5.4 [26,47]

Developed [26,35,40,47,49]

AQOL (r = 0.543) [41]

Viral load [40]

Decline before and after diagnosis of SAE* [35,40]

EQ-5D-3L (r = 0.551) [41]

SF-6D*

HIV+ patients [4,18,50]

Developed [4,18,50-52]

55-2508

-

0.94 [18]

-

SF36 (r = 0.73-0.79) [18]

-

-

Change follow the change of health status [18]

0 [18]

6-10 [18]

HIV+

women [51]

VAS (r = 0.75) [18]

HIV+ IDUs [52]

SG*

HIV+ patients [4,6,17,26,37,40,53-56]

Developing [17,37,55]

75-450

-

0.41-0.42 [17]

-

TTO (r = 0.21-0.39) [17]

CD4 count groups [26,37,53]

-

Decline after diagnosis of SAE* [40]

7.6-11 [26,37,47]

0.8-22 [26,37,47]

VAS (r = 0.26-0.34) [17]

MOS-HIV (r = 0.14-0.15) [26,47]

Developed [4,6,26,40,47,53,54,56]

WHOQOL-BREF (r = 0.09-0.34) [37]

HIV stages [4]

Global rating of change [17]

TTO*

HIV+ patients [6,17,26,40,53,54,56,57]

Developing [17]

66-450

-

0.71-0.83 [17]

-

Global rating of change [53]

CD4 count [40]

CD4 count group [26,53]

Improve over time [17]

Decline after diagnosis of SAE* [40]

4.4 [26,47]

18.3 [26,47]

SG (r = 0.21-0.39) [17]

Developed [6,26,40,47,53,54,56,57]

VAS (r = 0.45-0.61) [17]

MOS-HIV (r = 0.21-0.29) [26,47]

VAS*

HIV+ patient [4,6,17,26-30,37,39,40,42,44-46,48,53,54,56,58-71]

Developing [17,37,39,46,58,63,71]

16-2865

-

0.71-0.83 [17]

MOS-HIV [27]

Global rating of change [17]

CD4 count [28,40,61,64]

HIV stages [4,29]

Improve over time [58]

Decline after diagnosis of AE* [26,27] and OI* [27]

0-2 [18,26-28,37,47]

3.3-10.8 [18,26-28,37,47]

MOS-HIV (r = 0.33-0.72) [26,28,29,47,63]

EQ-5D-3L (r = 0.41-0.63) [28,29,39]

CD4 count groups [37,53]

EQ-5D-5L (r = 0.73) [48]

Developed [4,6,26-30,34,40-42,44,45,47,53,54,56,60,61,64-70]

HIV-RNA groups [64]

SG (r = 0.26-0.34) [17]

Viral load [28,64]

Decline before and after diagnosis of SAE* [40,64]

TTO (r = 0.45-0.61) [17]

WHOQOL-BREF (r = 0.36-0.54) [37]